Gonadotropin-releasing hormone analog treatment for the prevention of treatment-related ovarian failure and infertility in women of reproductive age with Hodgkin lymphoma.

Falorio S, Angrilli F, Fioritoni G

Leukemia & lymphoma1 Jun 2008Cited by 15 (Europe PMC)

PMID18452079DOI10.1080/10428190802035982PepBankPUB-18452079

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In a retrospective study of 61 women with Hodgkin lymphoma given monthly triptorelin during chemotherapy, 50 patients (82%) recovered regular menses.
In plain wordsAmong women with Hodgkin lymphoma given monthly triptorelin during chemotherapy, 50 recovered regular periods.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedRecovery of regular menses
Study
n = 61
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Regular menses recovery
50 patients
chemotherapy regimens with triptorelin
Regular menses recovery
82%
chemotherapy regimens with triptorelin
Source sentences
Summary
Fifty patients (82%) recovered regular menses, four patients (6%) reported menstrual abnormalities, and seven patients (12%) who were under salvage treatment became amenorrheic.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective study on treatment-related ovarian failure in 61 women with Hodgkin lymphoma who were under treatment from 1994 to 2006.
Summary · context
To minimize the risk of treatment-related gonadotoxicity, triptorelin (Decapeptyl), a gonadotropin-releasing hormone analog (GnRHa), was administered monthly.
Summary · context
All patients were treated with frontline polychemotherapy with or without radiotherapy.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1845207901
02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studySafety outcome
In women with Hodgkin lymphoma given monthly triptorelin during chemotherapy, four patients (6%) reported menstrual abnormalities.
In plain wordsAmong women with Hodgkin lymphoma given monthly triptorelin during chemotherapy, four reported abnormal periods.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedMenstrual abnormalities
Study
n = 61
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Menstrual abnormalities
4 patients
chemotherapy regimens with triptorelin
Menstrual abnormalities
6%
chemotherapy regimens with triptorelin
Source sentences
Summary
Fifty patients (82%) recovered regular menses, four patients (6%) reported menstrual abnormalities, and seven patients (12%) who were under salvage treatment became amenorrheic.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective study on treatment-related ovarian failure in 61 women with Hodgkin lymphoma who were under treatment from 1994 to 2006.
Summary · context
To minimize the risk of treatment-related gonadotoxicity, triptorelin (Decapeptyl), a gonadotropin-releasing hormone analog (GnRHa), was administered monthly.
Summary · context
All patients were treated with frontline polychemotherapy with or without radiotherapy.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1845207902
03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studySafety outcome
In women with Hodgkin lymphoma given monthly triptorelin, seven patients (12%) who were under salvage treatment became amenorrheic.
In plain wordsAmong women with Hodgkin lymphoma given monthly triptorelin, seven who were under salvage treatment stopped menstruating.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedAmenorrhea during salvage treatment
Study
n = 7
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Amenorrhea
7 patients
salvage treatment subgroup
Source sentences
Summary
Fifty patients (82%) recovered regular menses, four patients (6%) reported menstrual abnormalities, and seven patients (12%) who were under salvage treatment became amenorrheic.
4 context sentences(design, population, supporting numbers)
Summary · context
Seven refractory or relapsed patients received salvage treatment, and six of these patients further received peripheral blood stem cell transplantation.
Summary · context
We conducted a retrospective study on treatment-related ovarian failure in 61 women with Hodgkin lymphoma who were under treatment from 1994 to 2006.
Summary · context
To minimize the risk of treatment-related gonadotoxicity, triptorelin (Decapeptyl), a gonadotropin-releasing hormone analog (GnRHa), was administered monthly.
Summary · context
All patients were treated with frontline polychemotherapy with or without radiotherapy.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1845207903
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In women with Hodgkin lymphoma given monthly triptorelin during chemotherapy, 13 patients who attempted conception after treatment conceived.
In plain wordsAfter chemotherapy with monthly triptorelin, 13 women with Hodgkin lymphoma who attempted conception became pregnant.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedConception after treatment
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Conception
13 patients
patients attempting conception
Source sentences
Summary
After the completion of treatment, 13 patients who attempted conception conceived.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective study on treatment-related ovarian failure in 61 women with Hodgkin lymphoma who were under treatment from 1994 to 2006.
Summary · context
To minimize the risk of treatment-related gonadotoxicity, triptorelin (Decapeptyl), a gonadotropin-releasing hormone analog (GnRHa), was administered monthly.
Summary · context
All patients were treated with frontline polychemotherapy with or without radiotherapy.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1845207904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.